Diagnosing Fabry Nephropathy: Enzyme Tests, Genetic Testing and Urine Protein Checks

The letter from the kidney clinic was polite and short. A man in his late thirties, tired for years and treated for what everyone assumed was ordinary high blood pressure, had protein in his urine that would not go away. His nephrologist wanted one more blood test before deciding anything. Nobody had said the word Fabry out loud yet, but the sample was on its way to a metabolic laboratory.

That scene plays out more often than most people realize. Fabry disease hides behind common diagnoses, and the kidney is frequently where it first refuses to stay hidden. Choosing the right fabry disease diagnosis test, in the right order, is the difference between an answer and another decade of guessing.

This explainer walks through the enzyme assay, the gene sequencing and the humble urine protein check, what each can and cannot tell you, and why the three belong together rather than in competition.

What is Fabry nephropathy, and why does the kidney take the hit?

Fabry disease is an inherited condition in which the body cannot properly break down a fatty substance called globotriaosylceramide, usually shortened to Gb3. The job of clearing it belongs to an enzyme named alpha-galactosidase A, which works inside lysosomes, the recycling compartments inside every cell. When the enzyme is missing or faulty, Gb3 piles up like paper in a jammed shredder.

Nephropathy simply means kidney damage, so Fabry nephropathy is kidney injury caused by that build-up. The kidney is vulnerable for a mechanical reason. Its filtering units, the glomeruli, depend on specialized cells called podocytes that wrap around tiny blood vessels and hold back protein. Podocytes are long-lived and do not divide, so Gb3 accumulates in them for decades. Once they are damaged, protein leaks into the urine, and the filtering capacity slowly falls, as described in the NIH GeneReviews summary of the condition.

The same storage process affects blood vessel lining, heart muscle, nerve fibres and the sweat glands. That is why people with Fabry may describe burning pain in the hands and feet, an inability to sweat, or a pattern of small dark red skin spots, alongside kidney findings. None of these features is unique to Fabry, which is part of the diagnostic puzzle.

MedlinePlus Genetics estimates that the condition affects roughly 1 in 40,000 to 60,000 males. The true figure is probably higher, because late-onset forms produce few early clues and are found mainly when someone looks. In kidney medicine, that means thinking of Fabry when proteinuria or reduced filtration has no obvious cause, particularly in younger adults.

How is Fabry disease diagnosed? Which fabry disease diagnosis test comes first?

There is no single stand-alone test. Fabry disease is confirmed by combining biochemistry, genetics and a measure of organ involvement, and the order depends heavily on who is being tested.

For a male with suggestive findings, the first step is almost always the enzyme assay: a blood sample measuring how much alpha-galactosidase A activity is present in white blood cells or in a dried blood spot. According to the NIH GeneReviews chapter, markedly reduced or absent activity in a male is strongly supportive, and genetic testing then identifies the specific variant so that relatives can be tested and the type of disease can be characterized.

For a female, the sequence is usually reversed. Enzyme activity in women can fall anywhere from very low to entirely normal, so a normal result does not rule the condition out. GeneReviews and the Cleveland Clinic both note that molecular testing of the GLA gene is the reliable route in females.

Alongside these, a nephrologist typically orders urine studies: a urine albumin-to-creatinine ratio, a urine protein-to-creatinine ratio, and a blood creatinine to estimate the glomerular filtration rate, or eGFR, which is a calculated measure of how well the kidneys are clearing waste. These do not diagnose Fabry, but they tell the team whether the kidneys have already been affected.

A fourth element, a blood biomarker called lyso-Gb3, is increasingly used to support the diagnosis and to help interpret variants whose significance is uncertain. Putting these pieces together, rather than relying on any one of them, is what a careful fabry disease diagnosis test pathway looks like in practice.

How does the alpha galactosidase A test actually work?

The enzyme assay is a functional test. Rather than asking whether the gene is spelled correctly, it asks whether the enzyme does its job. A laboratory takes white blood cells from a blood sample, or a small dried blood spot on filter paper, and mixes the extracted material with an artificial substrate that alpha-galactosidase A normally cleaves. When the enzyme cuts the substrate, it releases a fluorescent signal. Less fluorescence means less enzyme activity.

Results are reported as activity relative to a reference range established by that laboratory. In males with the classic form, the NIH GeneReviews chapter describes activity that is very low or undetectable. In males with later-onset variants, residual activity is present but reduced, which is precisely why those men develop problems later and more selectively, often in the heart or kidney alone.

Two practical points matter for anyone waiting on this test. First, the dried blood spot version is convenient and widely used for screening, but a low screening result is generally confirmed by a leukocyte assay or by genetic testing, because screening methods trade some precision for accessibility. Second, sample handling matters. Delays in transport or exposure to heat can degrade the enzyme and produce a falsely low reading, so laboratories may occasionally request a repeat.

The enzyme test cannot tell you how severe the disease will be, how far it has progressed, or which organs are involved. It answers one question well: in a male, is the enzyme working? For everything else, it hands the baton to the other tests.

Why can the enzyme test miss fabry disease in females?

Fabry disease is X-linked, meaning the GLA gene sits on the X chromosome. Men have one X chromosome, so a single faulty copy leaves them with no working version. Women have two, and here biology introduces a twist called X-inactivation.

In each of a woman’s cells, one X chromosome is switched off early in development, essentially at random. Some cells silence the healthy copy and rely on the faulty one; others do the reverse. The result is a mosaic. Averaged across a blood sample, enzyme activity may land in the normal range even though many cells in the kidney, heart or nerves are storing Gb3. The NIH GeneReviews chapter states plainly that enzyme analysis is unreliable for identifying heterozygous females for this reason.

This is not an academic quibble. For decades women were labelled carriers, a term that implied they would not become ill. Mainstream sources including MedlinePlus Genetics now describe that women can develop symptoms ranging from mild to as severe as those seen in men, though usually later in life. Skewed X-inactivation, where most cells happen to silence the healthy copy, can leave a woman with disease that looks much like a man’s.

The practical consequence is straightforward: when Fabry is suspected in a woman, or when a male relative has been diagnosed, sequencing of the GLA gene is the appropriate test. A normal enzyme result in a woman should never be used to close the door. Lyso-Gb3 in blood can add supporting evidence in women, since it tends to reflect the burden of stored material rather than the activity of a single cell type, but it does not replace genetic confirmation.

What does GLA gene testing show, and what if the result is uncertain?

Genetic testing reads the sequence of the GLA gene, usually from a blood sample and sometimes from saliva or a cheek swab, and compares it to the reference sequence. A variant is any difference from that reference. Laboratories classify variants on a scale from benign to pathogenic, with a middle category called a variant of uncertain significance, or VUS, when the evidence is not yet strong enough to decide.

MedlinePlus Genetics notes that hundreds of different GLA variants have been identified. Some abolish enzyme production and cause classic, multi-organ disease. Others reduce activity partially and are associated with later-onset disease concentrated in one organ. A number of well-studied variants are considered benign or of very limited effect, and a few remain genuinely debated.

Testing is most useful when the whole coding sequence is examined, not just a panel of common variants, because Fabry variants are often private to a single family. Where standard sequencing finds nothing but suspicion remains strong, laboratories may look for larger deletions or duplications, or for changes in the non-coding regions that alter how the gene is read.

A VUS is the result families find hardest. It does not mean the person has Fabry, and it does not mean they do not. In that situation the NIH GeneReviews chapter describes how clinicians weigh other evidence: the enzyme level in males, plasma lyso-Gb3, kidney or heart findings, and whether the variant tracks with disease in affected relatives. Sometimes a kidney biopsy showing characteristic storage settles the question. Sometimes the honest answer is to monitor and revisit as the scientific literature matures. Genetic counselling, before and after testing, helps people understand what a given classification means for them and their family.

What do urine protein checks reveal about Fabry kidneys?

Protein in the urine is the kidney’s early warning system. Healthy glomeruli keep almost all albumin, the main blood protein, inside the bloodstream. When podocytes are injured, albumin slips through. Laboratories measure this in two ways: the albumin-to-creatinine ratio, which detects small amounts and is sensitive to early damage, and the protein-to-creatinine ratio, which captures heavier leakage. Both are done on a simple spot urine sample, ideally first thing in the morning, and both are corrected for how concentrated the urine is.

In Fabry disease, the NIH GeneReviews chapter describes albuminuria as one of the earliest measurable kidney signs, frequently appearing before any fall in eGFR. That order matters. By the time filtration is clearly reduced, a substantial amount of irreversible scarring has often occurred. Catching protein leak early gives the treating team time to act.

Urine tests carry a limitation worth stating clearly: they are not specific. Diabetes, hypertension, and dozens of other kidney conditions also cause proteinuria. A positive urine protein check in someone without a known cause is a reason to think about Fabry, not a diagnosis of it. Conversely, a clean urine test in someone with a confirmed GLA variant does not mean the kidney is untouched; storage can be present in podocytes before protein appears.

Fabry can also affect the kidney’s ability to concentrate urine and to handle salt, so some people notice passing large volumes of dilute urine. Under the microscope, a laboratory may see fat-laden cells in the urine sediment, sometimes described as having a Maltese-cross appearance under polarized light. It is a clue, not a confirmation, but an experienced eye will take it seriously.

Is a kidney biopsy still part of the fabry disease diagnosis test workup?

Not routinely, and that is a genuine change from earlier decades. Once enzyme and genetic testing became widely available, the biopsy moved from centre stage to a supporting role. It remains valuable in three situations.

The first is the unexpected finding. Many people with late-onset Fabry are discovered when a biopsy taken for unexplained proteinuria shows the pathologist something distinctive: podocytes swollen with lamellar inclusions that resemble stacked layers, often called myelin figures or zebra bodies under the electron microscope. When a pathologist sees these, the enzyme and genetic tests follow.

The second is the uncertain variant. If someone carries a VUS and has kidney findings, tissue evidence of Gb3 storage can support the conclusion that the variant is doing harm. The NIH GeneReviews chapter lists biopsy findings among the evidence used to interpret such cases.

The third is staging. A nephrologist may want to know how much scarring, or fibrosis, is already present before planning management, because the degree of established damage influences what is realistic to expect. The Fabry-specific recommendations published in the peer-reviewed literature, including the adult management consensus indexed on PubMed, describe biopsy as useful for assessing the extent of irreversible change in selected patients rather than as a requirement for diagnosis.

A biopsy involves a needle sample of kidney tissue taken under local anaesthetic with imaging guidance. Bleeding is the main risk, and people are usually observed for several hours afterwards. Whether it adds enough information to justify that risk is a judgment for the treating team, made case by case.

Enzyme test vs genetic test vs urine protein: a side-by-side summary

Each test answers a different question, which is why guidelines describe them as complementary. The table below summarizes what patients most often want to know about each one, drawing on the NIH GeneReviews chapter and the Cleveland Clinic overview.

Test	What it measures	Best at	Main limitation	Sample
Alpha-galactosidase A enzyme assay	How much working enzyme is present	Diagnosing males; screening	Can be normal in females; sensitive to sample handling	Blood or dried blood spot
GLA gene sequencing	Whether a disease-causing variant is present	Diagnosing females; confirming males; family testing	Variants of uncertain significance need further evidence	Blood, saliva or cheek swab
Plasma lyso-Gb3	Amount of stored breakdown product in blood	Supporting diagnosis; helping interpret uncertain variants	Does not replace enzyme or genetic testing; ranges vary by laboratory	Blood
Urine albumin or protein to creatinine ratio	Protein leaking through the kidney filter	Detecting early kidney involvement; tracking change	Not specific to Fabry; can be normal despite storage	Spot urine
eGFR from blood creatinine	Estimated filtering capacity	Staging kidney function over time	Falls late; influenced by muscle mass and hydration	Blood
Kidney biopsy	Direct view of tissue storage and scarring	Unexpected discovery; resolving uncertain cases; staging	Invasive; bleeding risk	Tissue

Read across a row and you see why no single line item is sufficient. Read down the columns and a pattern emerges: the enzyme and gene tests establish whether Fabry is present, while the urine and blood kidney tests establish what it has already done. A complete assessment needs both halves.

Who is usually tested for Fabry, and who is usually asked to wait?

Testing is targeted rather than universal, and the trigger is usually a pattern that does not fit. The Cleveland Clinic and NIH GeneReviews describe several groups in whom clinicians commonly consider a fabry disease diagnosis test.

People with unexplained kidney disease, especially proteinuria or reduced eGFR in a younger adult without diabetes or long-standing hypertension, sit near the top of the list. So do those with a thickened heart muscle, known as hypertrophic cardiomyopathy, without an obvious cause, and people who have had a stroke at an unusually young age. Childhood-onset burning pain in the hands and feet, reduced sweating, recurrent unexplained fevers, or a distinctive corneal pattern spotted during an eye examination can prompt referral from other specialties.

Relatives of a confirmed case form the other major group. Because inheritance is X-linked, the pattern is predictable: an affected man passes the variant to all his daughters and none of his sons; an affected woman has a one-in-two chance of passing it to each child, regardless of sex, as MedlinePlus Genetics explains. Cascade testing of a family frequently identifies people who had symptoms but no diagnosis.

Who is asked to wait? In practice, children in a family with a late-onset variant and no symptoms are sometimes monitored rather than tested immediately, so that decisions about testing can involve them as they grow. People with vague symptoms and no supporting findings may be offered a period of observation first. Neither delay is a refusal; it reflects a judgment that the result would not change management yet, and that a genetic label carries weight of its own. These decisions belong to the individual, their family and the clinical team, ideally with a genetic counsellor in the room.

At what age is Fabry disease typically diagnosed?

Later than it should be, in most cases. That is the uncomfortable consensus across mainstream sources, and the reasons are instructive.

MedlinePlus Genetics describes two broad presentations. In the classic form, which mostly affects males with little or no enzyme activity, symptoms begin in childhood: episodes of burning pain in the extremities, gut upset, heat intolerance and the small red skin spots known as angiokeratomas. Yet children with these complaints are commonly told they have growing pains or anxiety, and years can pass before anyone joins the dots. The later-onset form, seen in males with some residual enzyme activity and in many females, produces few or no childhood clues and typically comes to light in adulthood when the heart or kidney is already affected.

The NIH GeneReviews chapter notes that in untreated males with classic disease, kidney function tends to decline through adulthood, with kidney failure historically developing by the third to fifth decade of life. Diagnosis at that stage means much of the damage is established.

Two developments are shifting the age at diagnosis. Some regions have added Fabry to newborn screening programmes, which pick up infants long before symptoms; GeneReviews observes that these programmes detect later-onset variants far more often than classic ones, raising new questions about how to follow children who may not become unwell for decades. Second, screening in adult cardiology and nephrology clinics is finding people in midlife who would otherwise have been missed.

The honest answer, then, is that diagnosis can occur at any age from the first week of life to the seventh decade, and the age says more about the route to discovery than about the disease itself.

What happens in the days and weeks after a positive Fabry result?

A confirmed result rarely means a single appointment. Instead it opens a period of mapping: finding out which organs are involved and how far things have progressed, so that a plan can be built around facts rather than fear.

On the kidney side, the team typically repeats the urine albumin and protein ratios, checks eGFR, and reviews blood pressure, since controlling pressure protects any kidney under strain. If a biopsy has not been done, its value is discussed. The adult management recommendations indexed on PubMed describe a baseline assessment that also includes the heart, usually an electrocardiogram and echocardiogram to look at rhythm and muscle thickness, and often a cardiac MRI. Brain imaging may be arranged given the stroke risk associated with the condition, and hearing testing is commonly included because the inner ear is affected in some people.

Genetic counselling sits alongside this. The counsellor explains the inheritance pattern, helps draw a family tree, and discusses which relatives might be offered testing and how to raise the subject. Many people find this the hardest part, particularly parents realizing a variant may have come from them. Counsellors are trained for exactly that conversation.

Once the picture is complete, the team discusses management. Disease-specific treatments exist, including enzyme replacement therapy, which supplies a laboratory-made version of the missing enzyme by infusion, and oral chaperone therapy, which stabilizes certain faulty enzyme variants so they can work better; the latter is suitable only for specific variants. Which approach, if any, is appropriate depends on the variant, the organs involved, age and personal circumstances, and is decided by the prescribing clinician. Follow-up then settles into a rhythm of regular kidney, heart and symptom checks at intervals the team sets.

What people often get wrong about Fabry testing

Fabry attracts a particular set of misunderstandings, partly because it is rare and partly because older textbooks got some things wrong. A few deserve correcting directly.

Fabry is not an autoimmune disease. Autoimmunity means the immune system attacks the body’s own tissue; Fabry is a metabolic storage disorder caused by a single faulty gene, as MedlinePlus Genetics explains. The distinction matters because autoimmune conditions are investigated with antibody tests and treated with immune-modulating drugs, none of which apply here. Some people with Fabry do develop antibodies against infused replacement enzyme, which can complicate treatment, but that is a response to therapy rather than the cause of the disease.

Women are not merely carriers. That word implies a person who passes on a condition without experiencing it. The NIH GeneReviews chapter is clear that heterozygous females frequently develop symptoms, sometimes serious ones, and should be assessed and followed in their own right.

A normal enzyme test does not exclude Fabry. It does so reasonably well in males, but not in females, where genetic testing is required.

A normal urine test does not mean the kidneys are fine. Storage in podocytes precedes protein leak, and protein leak precedes any measurable drop in filtration.

Finding a GLA variant does not automatically mean disease. Some variants are benign or associated with very mild effects, and a VUS is exactly that: uncertain. Interpretation requires the whole clinical picture.

Finally, a diagnosis late in life is not a failure. Late-onset disease is designed, in a sense, to be missed; recognizing it at all opens the door to monitoring and, where appropriate, treatment that would otherwise never have been considered.

Is Fabry considered a disability, and what does a diagnosis change day to day?

People searching this question usually want two things: an idea of what the condition will mean for work and daily life, and a sense of whether formal support is available. Both deserve a plain answer.

Whether Fabry counts as a disability is not a medical judgment but an administrative one, and the rules differ between countries, insurers and employers. In most systems, eligibility depends on how the condition affects function, such as the ability to work, rather than on the diagnosis itself. A person with a late-onset variant and stable kidney function may meet no criteria at all; someone with advanced kidney disease, heart involvement or disabling pain may qualify for substantial support. Social workers attached to metabolic or kidney services, and patient advocacy organizations, are the right people to ask about a specific jurisdiction.

What the diagnosis changes medically is more predictable. It moves someone from the general population into a structured surveillance programme. Kidney function and urine protein are tracked over time, as are heart rhythm and structure, so that changes are caught early. It also reframes older symptoms: the childhood pain episodes, the inability to tolerate heat, the gut upset that was blamed on stress. Many people describe relief at finally having an explanation, even while grappling with what it means.

The MedlinePlus Genetics and Cleveland Clinic overviews describe Fabry as a lifelong condition whose course varies widely between individuals, even within a family. That variability is the honest reason no one can predict, at diagnosis, exactly how much the condition will limit a given person. What can be said is that early recognition, blood pressure control, attention to cardiovascular risk and appropriate disease-specific treatment, decided with the treating team, are the tools that give people the best opportunity to keep doing what matters to them.

Questions to ask your care team about Fabry testing

Consultations about rare diseases move fast, and it is easy to leave with more questions than you arrived with. Writing a few down beforehand changes the dynamic. The following are the ones patients and families most often wish they had asked.

• Which test are you ordering first, and what result would make you order the next one?
• If I am female, will the enzyme test be enough, or do I need GLA gene testing regardless?
• How will you tell whether my kidneys are already affected, and how often will you recheck urine protein and eGFR?
• Is a kidney biopsy likely to add information in my case, and what are its risks?
• If my genetic result is a variant of uncertain significance, what additional evidence would help interpret it?
• Can I see a genetic counsellor before results come back, and will they help me talk to my relatives?
• Which of my family members should be offered testing, and in what order?
• Do you know whether my specific variant is associated with classic or later-onset disease?
• Which other organs will you assess, and what does that involve?
• What are the treatment options for someone with my variant and my level of organ involvement, and what are the reasons for and against starting now?
• How will we know over time whether the plan is working?
• Who do I contact between appointments if something changes?

It is reasonable to ask for a written summary of the diagnostic results, including the exact variant name, since relatives tested elsewhere will need it. It is equally reasonable to ask the same question twice. Teams who manage Fabry regularly expect it, and a good clinician would rather explain again than have you leave uncertain.

When to call your doctor: red-flag signs during and after Fabry diagnosis

Most of the diagnostic journey unfolds at a measured pace, but a few situations need prompt attention rather than waiting for the next scheduled visit. These apply whether Fabry is suspected, newly confirmed or long established.

Seek emergency care immediately for sudden weakness or numbness on one side of the body, facial drooping, slurred speech, sudden confusion or loss of vision, because Fabry raises the risk of stroke, including in younger adults, as the Cleveland Clinic notes. Do the same for chest pain, fainting, a racing or very slow heartbeat, or sudden severe breathlessness, since heart rhythm problems and heart failure are recognized complications.

Call your care team the same day if you notice a marked reduction in urine output, swelling of the ankles, legs or around the eyes, blood in the urine, or urine that has become persistently foamy, all of which can signal a change in kidney function or protein leak. New or worsening shortness of breath when lying flat, or unexplained rapid weight gain over a few days, also warrants a call.

If you have had a kidney biopsy, contact the team urgently for heavy or persistent blood in the urine, severe back or flank pain, fever, dizziness or fainting.

Pain crises that are more severe or prolonged than your usual pattern, especially with fever, deserve a conversation rather than endurance; there are approaches to managing them that your team can discuss. Ringing in the ears with sudden hearing loss, or any new neurological symptom, should be reported.

Finally, if you are waiting for results and your symptoms change substantially, do not assume the appointment date is fixed. A phone call can bring it forward. Every decision about tests, treatment and timing rests with your treating team, but they can only act on what they know.

Frequently asked questions

How is Fabry disease diagnosed?

Fabry disease is diagnosed by measuring alpha-galactosidase A enzyme activity in blood and confirming a disease-causing variant in the GLA gene through genetic testing. In males, low enzyme activity is usually the first clue; in females, genetic testing is essential because enzyme levels can be normal. Urine protein checks, kidney function tests and heart assessments then show which organs are involved. A biomarker called lyso-Gb3 may support the diagnosis in uncertain cases.

At what age is Fabry disease typically diagnosed?

Diagnosis ranges from the newborn period to late adulthood, depending on the type and how it is discovered. Classic Fabry produces symptoms in childhood, though recognition is often delayed by years. Later-onset forms typically come to light in adulthood when heart or kidney problems appear. Newborn screening in some regions now identifies infants before symptoms, while screening in adult kidney and cardiology clinics is finding people in midlife who were previously missed.

Is Fabry an autoimmune disease?

No. Fabry is an inherited lysosomal storage disorder caused by a faulty GLA gene, which leaves cells unable to break down a fatty substance called Gb3. Autoimmune diseases involve the immune system attacking the body’s own tissues, which is not what happens here. Some people receiving enzyme replacement therapy develop antibodies against the infused enzyme, but that is a reaction to treatment, not the cause of the condition.

Is Fabry considered a disability?

That depends on the legal and administrative rules where you live, not on the diagnosis alone. Most systems assess how much a condition limits daily function or the ability to work. Someone with mild late-onset Fabry and stable kidneys may not qualify, while a person with advanced kidney disease, heart involvement or severe pain may be eligible for support. Social workers in metabolic services and patient organizations can advise on specific criteria.

What does the alpha galactosidase A test involve?

It is a blood test, either a standard sample or a few drops dried on filter paper. The laboratory mixes extracted white blood cells with a substance the enzyme normally cuts and measures the fluorescent signal released; less signal means less enzyme activity. Results are compared to the laboratory’s reference range. Samples must be handled carefully, since heat or delay can degrade the enzyme and produce a falsely low result that may need repeating.

Is GLA gene testing done with blood or saliva?

Both are possible. Most laboratories use a blood sample, but saliva or a cheek swab can supply enough DNA for sequencing. The test reads the GLA gene and classifies any variant found as benign, pathogenic or of uncertain significance. If standard sequencing is negative but suspicion remains high, laboratories may look for larger deletions or duplications. Genetic counselling before and after testing helps you understand what a given result means.

Can a woman have a normal enzyme test and still have Fabry disease?

Yes. Because women have two X chromosomes and one is randomly switched off in each cell, enzyme activity measured in blood can average out to a normal value even when many cells in the kidney or heart are storing Gb3. This is why the NIH GeneReviews chapter describes enzyme testing as unreliable in females and recommends GLA gene sequencing instead. A normal enzyme result in a woman should never be used to exclude the condition.

What are the fabry disease kidney symptoms people should know about?

Early kidney involvement often causes no symptoms at all, which is why urine protein checks matter. Some people notice foamy urine from protein leak, passing large volumes of dilute urine, or swelling of the ankles as the condition advances. Fatigue, high blood pressure and reduced appetite can accompany falling kidney function. These features are not specific to Fabry and are shared with many kidney conditions, so they prompt testing rather than confirm a diagnosis.

Do all my relatives need testing if I am diagnosed with Fabry?

Not all, but the X-linked pattern makes it clear who is at risk. An affected man passes the variant to every daughter and no son; an affected woman has a one-in-two chance of passing it to each child. A genetic counsellor helps draw the family tree and identify who could be offered testing. Adults decide for themselves; for children, families and clinicians weigh the benefit of early monitoring against the weight of a genetic label.

Why is lyso-Gb3 measured, and does it replace other tests?

Lyso-Gb3 is a breakdown product of the stored substance in Fabry disease, and its level in blood tends to reflect the overall burden of storage. It is useful for supporting a diagnosis, especially in women and in people with a variant of uncertain significance, and some teams track it over time. It does not replace enzyme or genetic testing, and reference ranges vary between laboratories, so your team interprets it alongside the other results.

References

• MedlinePlus Genetics: Fabry disease
• MedlinePlus Genetics: GLA gene
• NIH GeneReviews: Fabry Disease
• Cleveland Clinic: Fabry Disease

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.